Add this result to my export selection Talc for pleurodesis: adverse effects Source: GOV UK (Add filter) Source: Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter) Published by Medicines and Healthcare products Regulatory Agency, 11 December 2014 We have recently advised that talc preparations for pleurodesis are to be considered as medicinal products. Read Summary Type: Safety Alerts (Remove filter)
Add this result to my export selection Co-proxamol withdrawal: reminder to prescribers Source: GOV UK (Add filter) Source: Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter) Published by Medicines and Healthcare products Regulatory Agency, 11 December 2014 Co-proxamol's phased withdrawal period lasts until the end of 2007 to enable patients to move to suitable alternatives. Read Summary Type: Safety Alerts (Remove filter)
Add this result to my export selection Herbal ingredient St John's wort may interact with antiepileptics Source: GOV UK (Add filter) Source: Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter) Published by Medicines and Healthcare products Regulatory Agency, 11 December 2014 Patients with epilepsy should not take products that contain St John’s wort as any antiepileptic medicine may interact with St John’s wort. Read Summary Type: Safety Alerts (Remove filter)
Add this result to my export selection Illegal herbal remedies containing Aristolochia: vigilance needed Source: GOV UK (Add filter) Source: Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter) Published by Medicines and Healthcare products Regulatory Agency, 11 December 2014 MHRA continues to identify cases of herbal medicines, particularly traditional Chinese medicines, which contain illegal and toxic Aristolochia or aristolochic acids. Read Summary Type: Safety Alerts (Remove filter)
Add this result to my export selection Ecoflac infusion solutions: risk of air embolism Source: GOV UK (Add filter) Source: Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter) Published by Medicines and Healthcare products Regulatory Agency, 11 December 2014 To avoid the risk of air embolism, these products should not be infused under pressure. Read Summary Type: Safety Alerts (Remove filter)
Add this result to my export selection Botulinum toxin products: rare but serious risks Source: GOV UK (Add filter) Source: Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter) Published by Medicines and Healthcare products Regulatory Agency, 11 December 2014 Products that contain botulinum toxin are associated with the risk of serious adverse reactions due to distant spread of toxin. Read Summary Type: Safety Alerts (Remove filter)
Add this result to my export selection Paraffin-based treatments: risk of fire hazard Source: GOV UK (Add filter) Source: Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter) Published by Medicines and Healthcare products Regulatory Agency, 11 December 2014 Paraffin based products such as white soft paraffin can set on fire easily. Read Summary Type: Safety Alerts (Remove filter)
Add this result to my export selection Statins: interactions, and updated advice for atorvastatin Source: GOV UK (Add filter) Source: Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter) Published by Medicines and Healthcare products Regulatory Agency, 11 December 2014 Detailed recommendations for dose restrictions when used with some other drugs as interactions may increase the risk of adverse effects, or reduce the effectiveness of statin treatment. Read Summary Type: Safety Alerts (Remove filter)
Add this result to my export selection Oral anticancer medicines: risk of incorrect dosing Source: GOV UK (Add filter) Source: Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter) Published by Medicines and Healthcare products Regulatory Agency, 11 December 2014 Advice for healthcare professionals on potentially fatal outcomes of oral anticancer medicines if they are not prescribed, dispensed or administered properly. Read Summary Type: Safety Alerts (Remove filter)
Add this result to my export selection Desmomelt (desmopressin): report incidents on yellow card portal Source: GOV UK (Add filter) Source: Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter) Published by Medicines and Healthcare products Regulatory Agency, 11 December 2014 Healthcare professionals are encouraged to report all suspected adverse reactions (ADRs) on the yellow card porftal to melt formulations of desmopressin. Read Summary Type: Safety Alerts (Remove filter)